Aldeyra Therapeutics, Inc. — Investor Relations & Filings

Aldeyra Therapeutics is a biotechnology company developing medications for immune-mediated diseases. The company's therapeutic approach involves modulating immunological systems rather than inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Its portfolio of product candidates targets inflammatory cells associated with both ocular and systemic ailments. Aldeyra has investigational therapies in late-stage clinical development for conditions such as dry eye disease and allergic conjunctivitis, aiming to address medical needs not adequately met by existing treatments.